BNP Paribas Financial Markets Acquires New Holdings in Vera Therapeutics, Inc. (NASDAQ:VERA)

BNP Paribas Financial Markets acquired a new stake in Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 24,374 shares of the company's stock, valued at approximately $1,031,000.

Other hedge funds have also recently modified their holdings of the company. Huntington National Bank purchased a new position in shares of Vera Therapeutics in the fourth quarter valued at about $26,000. AlphaQuest LLC purchased a new position in shares of Vera Therapeutics during the fourth quarter valued at about $34,000. KBC Group NV increased its position in shares of Vera Therapeutics by 127.2% during the fourth quarter. KBC Group NV now owns 2,477 shares of the company's stock valued at $105,000 after buying an additional 1,387 shares during the period. Summit Investment Advisors Inc. increased its position in shares of Vera Therapeutics by 16.0% during the fourth quarter. Summit Investment Advisors Inc. now owns 4,639 shares of the company's stock valued at $196,000 after buying an additional 639 shares during the period. Finally, Moors & Cabot Inc. purchased a new position in shares of Vera Therapeutics during the fourth quarter valued at about $220,000. Hedge funds and other institutional investors own 99.21% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the stock. JPMorgan Chase & Co. reduced their price target on shares of Vera Therapeutics from $77.00 to $71.00 and set an "overweight" rating on the stock in a research report on Tuesday, March 4th. HC Wainwright assumed coverage on shares of Vera Therapeutics in a research report on Monday, May 5th. They set a "buy" rating and a $75.00 price target on the stock. Wedbush reduced their price target on shares of Vera Therapeutics from $34.00 to $26.00 and set a "neutral" rating on the stock in a research report on Wednesday, May 7th. Guggenheim boosted their price target on shares of Vera Therapeutics from $59.00 to $61.00 and gave the company a "buy" rating in a research report on Thursday, February 27th. Finally, The Goldman Sachs Group initiated coverage on shares of Vera Therapeutics in a research report on Tuesday, January 28th. They set a "buy" rating and a $58.00 price target on the stock. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of $63.33.

Vera Therapeutics Stock Up 0.1%

VERA traded up $0.01 during midday trading on Monday, reaching $19.64. The company's stock had a trading volume of 1,064,297 shares, compared to its average volume of 782,385. The firm has a market capitalization of $1.25 billion, a price-to-earnings ratio of -7.52 and a beta of 1.28. The company has a current ratio of 13.76, a quick ratio of 13.76 and a debt-to-equity ratio of 0.17. Vera Therapeutics, Inc. has a 1 year low of $18.53 and a 1 year high of $51.61. The stock's 50-day moving average is $22.58 and its 200-day moving average is $32.79.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.06). During the same period in the previous year, the company posted ($0.56) EPS. As a group, research analysts expect that Vera Therapeutics, Inc. will post -2.89 EPS for the current year.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.